Danaher Slashes 2026 Outlook Despite Q2 Beat; Bioprocessing Orders Surge
DHR is trading near its 52-week low of $160.93 (11% above the low) on elevated volume (5.6× avg).
Summary
Danaher cut its full-year core revenue growth guidance to 3%-4% from 3%-6%, citing weaker respiratory testing revenue, even as Q2 earnings beat estimates. The stock fell sharply on the guidance cut. Operating cash flow was $1.534B with free cash flow of $1.265B. Bioprocessing orders grew mid-teens, but revenue was hit by a ~$100M shipment deferral into next year. Separately, Leica Biosystems agreed to acquire StatLab Medical Products for $250M, a deal expected to close by end-2026 and be accretive to adjusted EPS in year one. This follows the Q2 beat reported yesterday and adds granularity on cash generation and the StatLab acquisition.
At the time of this announcement, DHR was trading at $178.80 on NYSE in the Life Sciences sector, with a market capitalization of approximately $126.7B. The 52-week trading range was $160.93 to $242.80. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.